2016 AHA LifeScience Monday-Chie-San

C. Michael Gibson during LBCT: An OPen-label, Randomized, Controlled, Multicenter Study ExplorIng TwO TreatmeNt StratEgiEs of Rivaroxaban and a Dose-Adjusted Oral Vitamin K Antagonist TreatmeNt Strategy in Subjects With Atrial Fibrillation Who Undergo Percutaneous Coronary Intervention PIONEER AF-PCI

New Orleans, LA - AHA 2016 Scientific Sessions - C. Michael Gibson during LBCT: An OPen-label, Randomized, Controlled, Multicenter Study ExplorIng TwO TreatmeNt StratEgiEs of Rivaroxaban and a Dose-Adjusted Oral Vitamin K Antagonist TreatmeNt Strategy in Subjects With Atrial Fibrillation Who Undergo Percutaneous Coronary Intervention PIONEER AF-PCI here today, Monday November 14, 2016 at the American Heart Association's Scientific Sessions being held here at the Ernest Morial Convention Center. Scientific Sessions is the leading cardiovascular meeting for basic, translational, clinical and population science, in the United States, with more than 19,000 cardiovascular experts from over 105 countries attending the meeting. Photo by © AHA/Scott Morgan 2016, C. Michael Gibson

GibsonAHA 2016C. Michael GibsonControlledLBCT An OPenlabelMulticenter Study ExplorIng TwO TreatmeNt StratEgiEs of Rivaroxaban and a DoseAdjusted Oral Vitamin K Antagonist TreatmeNt Strategy in Subjects With Atrial Fibrillation Who Undergo Percutaneous Coronary Intervention PIONEER AFPCIRandomized